Difficulty: Medium
Average Score: 64%
Practice
The mechanism by which neostigmine improves contraction of myasthenic muscle involves
Correct answer
D
Rationale
Neostigmine is a reversible acetylcholinesterase inhibitor used in the treatment of myasthenia gravis, a neuromuscular disease characterized by muscle weakness and fatigue. The correct answer is D) All of the above.
Neostigmine improves muscle contraction in myasthenic muscle by increasing the availability of acetylcholine at the neuromuscular junction. It achieves this through a combination of mechanisms:
A) Repetitive binding of acetylcholine to receptors: Neostigmine inhibits the enzyme acetylcholinesterase, which normally degrades acetylcholine. By preventing its breakdown, more acetylcholine is available to bind to and activate nicotinic receptors on the motor end-plate, leading to improved muscle contraction.
B) Diffusion of acetylcholine to a wider area: With acetylcholinesterase inhibited, acetylcholine remains in the synaptic cleft for a longer duration, allowing it to diffuse over a wider area and interact with more receptors, enhancing muscle stimulation.
C) Activation of motor end-plate receptors by neostigmine itself: Neostigmine can also directly bind to and activate nicotinic receptors on the motor end-plate, further contributing to enhanced muscle contraction.
The incorrect options can be ruled out for the following reasons:
- Option A is incorrect as neostigmine does not involve repetitive binding of acetylcholine to receptors directly but rather increases the amount of acetylcholine available for binding.
- Option B is incorrect as neostigmine does not affect the diffusion of acetylcholine but rather its concentration at the neuromuscular junction.
- Option C is incorrect because while neostigmine can indirectly activate motor end-plate receptors by increasing acetylcholine levels, it does not directly activate these receptors itself.
Understanding the pharmacological actions of neostigmine in enhancing neuromuscular transmission is crucial for healthcare professionals prescribing and administering this medication to patients with myasthenia gravis. This knowledge ensures optimal treatment outcomes and patient safety.
Neostigmine improves muscle contraction in myasthenic muscle by increasing the availability of acetylcholine at the neuromuscular junction. It achieves this through a combination of mechanisms:
A) Repetitive binding of acetylcholine to receptors: Neostigmine inhibits the enzyme acetylcholinesterase, which normally degrades acetylcholine. By preventing its breakdown, more acetylcholine is available to bind to and activate nicotinic receptors on the motor end-plate, leading to improved muscle contraction.
B) Diffusion of acetylcholine to a wider area: With acetylcholinesterase inhibited, acetylcholine remains in the synaptic cleft for a longer duration, allowing it to diffuse over a wider area and interact with more receptors, enhancing muscle stimulation.
C) Activation of motor end-plate receptors by neostigmine itself: Neostigmine can also directly bind to and activate nicotinic receptors on the motor end-plate, further contributing to enhanced muscle contraction.
The incorrect options can be ruled out for the following reasons:
- Option A is incorrect as neostigmine does not involve repetitive binding of acetylcholine to receptors directly but rather increases the amount of acetylcholine available for binding.
- Option B is incorrect as neostigmine does not affect the diffusion of acetylcholine but rather its concentration at the neuromuscular junction.
- Option C is incorrect because while neostigmine can indirectly activate motor end-plate receptors by increasing acetylcholine levels, it does not directly activate these receptors itself.
Understanding the pharmacological actions of neostigmine in enhancing neuromuscular transmission is crucial for healthcare professionals prescribing and administering this medication to patients with myasthenia gravis. This knowledge ensures optimal treatment outcomes and patient safety.